Sign In
CPSI Share                                                                  
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​​
Publication Type: Medication Safety Alert
Single or Multiple Incident: Multiple
Date: 5/1/2019 12:00:00 AM
Country: Hong Kong

This alert discusses the patient safety incidents of bleeding in patients on anti-coagulants. Bleeding is the most common side effect of all oral anti-coagulants; patients taking oral anti-coagulants may have a higher risk of bleeding. For patients who are taking warfarin, the dose of warfarin would be adjusted according to the International Normalised Ratio (INR) as measured by regular blood tests. Two incidents of bleeding are briefly described. Recommendations for the safe use of anticoagulants are provided in the alert.

Additional Details

anticoagulants, direct thrombin inhibitors, warfarin, Apixaban®, Dabigatran®, Edoxaban®, Rivaroxaban®, prochlorperazine
Medication/IV List:
antithrombotic agents (anticoagulants), including warfarin, low-molecular-weight heparin, IV unfractionated heparin, Factor Xa inhibitors (fondaparinux), direct thrombin inhibitors (e.g., argatroban, lepirudin,

Oral anti-coagulants: Case sharing and Tips